We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study
Read MoreHide Full Article
AC Immune SA (ACIU - Free Report) announced the initiation of the second-highest dosing group in its phase Ib/IIa study evaluating ACI-35.030 for the treatment of Alzheimer’s disease (AD). The primary objective of the study will be to evaluate the safety, tolerability and immunogenicity of different doses of ACI-35.030 over a 48-week treatment phase in patients with early AD. Other endpoints will assess clinical and cognitive parameters as well as additional immunogenicity and safety parameters.
The decision to advance ACI-35.030 to a higher dosing group is based on encouraging interim safety, tolerability and immunogenicity results from the initial dosing group. In the interim study, ACI-35.030 showed early target-specific antibody response against pTau after the first injection in the vast majority of patients in mild-to-moderate AD.
Shares of the company rose 18.5% after the announcement of the news. However, shares of the company have inched up 0.4% year to date compared with the industry’s growth of 9.5%.
ACI-35.030 is the first AD vaccine candidate designed to stimulate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology throughout the brain. It is being developed in collaboration with Johnson and Johnson’s (JNJ - Free Report) subsidiary, Janssen Pharmaceuticals, Inc.
AC Immune is also evaluating ACI-24, an anti-amyloid beta vaccine,whichis in phase Ib/II studies for two indications. The company also is testing semorinemab, an anti-Tau antibody,and crenezumab, an anti-amyloid antibody,in phase II studies. Both are being conducted in partnership with Genentech, part of Roche Holding AG (RHHBY - Free Report) .
Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study
AC Immune SA (ACIU - Free Report) announced the initiation of the second-highest dosing group in its phase Ib/IIa study evaluating ACI-35.030 for the treatment of Alzheimer’s disease (AD). The primary objective of the study will be to evaluate the safety, tolerability and immunogenicity of different doses of ACI-35.030 over a 48-week treatment phase in patients with early AD. Other endpoints will assess clinical and cognitive parameters as well as additional immunogenicity and safety parameters.
The decision to advance ACI-35.030 to a higher dosing group is based on encouraging interim safety, tolerability and immunogenicity results from the initial dosing group. In the interim study, ACI-35.030 showed early target-specific antibody response against pTau after the first injection in the vast majority of patients in mild-to-moderate AD.
Shares of the company rose 18.5% after the announcement of the news. However, shares of the company have inched up 0.4% year to date compared with the industry’s growth of 9.5%.
ACI-35.030 is the first AD vaccine candidate designed to stimulate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology throughout the brain. It is being developed in collaboration with Johnson and Johnson’s (JNJ - Free Report) subsidiary, Janssen Pharmaceuticals, Inc.
AC Immune is also evaluating ACI-24, an anti-amyloid beta vaccine,whichis in phase Ib/II studies for two indications. The company also is testing semorinemab, an anti-Tau antibody,and crenezumab, an anti-amyloid antibody,in phase II studies. Both are being conducted in partnership with Genentech, part of Roche Holding AG (RHHBY - Free Report) .
Zacks Rank &A Stock to Consider
AC Immune currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Emergent Biosolutions Inc. (EBS - Free Report) , carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>